Is Zoetis Inc. (ZTS) a Buy, Sell, or Hold?
NYSE : ZTS
Zoetis Inc.
$76.56 USD
-$0.35 (-0.46%)
- Volume
- 4.47M
- Average Volume
- 7.34M
- Market Capitalization
- $32.1B
- P/E Ratio
- 12.68
- Dividend Yield
- 2.69%
- Price Target
- $99.00
- Year High
- $160.48
- Year Low
- $71.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.34
- Current Ratio
- $3.15
Company Overview
NYSE
Kristin C. Peck
Drug Manufacturers - General
Healthcare
ZTS
14500
US
USD
Liquidity Metrics
2.86
3.15
1.91
0.94
0.34
Sales & Valuation
$9.47B
3.38
10.00
15.03
5.06
Profitability
$6.02
$2.67B
27.79%
34.79%
62.41%
17.44%
P/E Metrics
12.68
1.54
1.54
Analyst Price Target & Rating
$99.00
$160.00
$85.00
3/5
31 Analysts
-22.67%
Poll Results
About Zoetis Inc. (NYSE:ZTS) Stock
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as flea ... s, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
2026-07-17 18:51:00
New York, New York--(Newsfile Corp. - July 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline. SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2026-07-17 12:37:00
BENSALEM, Pa., July 17, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
2026-07-17 12:00:00
New York, New York--(Newsfile Corp. - July 17, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
2026-07-17 10:17:00
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-16 15:39:00
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZOETIS INC. (ZTS), CLICK HERE BEFORE JULY 27, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
2026-07-16 14:12:00
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.
2026-07-16 12:00:00
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”).
2026-07-16 10:09:00
Wall Street's Reassessment of Zoetis Accelerated as Analyst Downgrades Followed Each Corrective Disclosure, Reflecting Growing Skepticism That Management's Companion Animal Growth Narrative Was Built on Concealed Competitive and Safety Deterioration NEW YORK, July 16, 2026 /PRNewswire/ -- Sell-side coverage of Zoetis Inc. (NYSE: ZTS) shifted dramatically over a nine-month span successive revelations forced analysts to reprice the animal health leader's growth assumptions. SueWallSt notifies investors who purchased ZTS securities between January 14, 2025 and May 6, 2026 that a securities class action has been filed.
Frequently Asked Questions
-
What is the current Zoetis Inc. (ZTS) stock price?
-
Zoetis Inc.(NYSE:ZTS) stock price is $76.56 in the last trading session. During the trading session, ZTS stock reached the peak price of $160.48 while $71.47 was the lowest point it dropped to. The percentage change in ZTS stock occurred in the recent session was --0.46% while the dollar amount for the price change in ZTS stock was -$0.35.
-
ZTS's industry and sector of operation?
-
The NYSE listed ZTS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of ZTS?
-
Jamie Brannan | Executive Vice President & Chief Commercial Officer
Kristin C. Peck | Chief Executive Officer & Director
Robert J. Polzer | Scientific Advisor
Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations
Rimma Driscoll | EVP of Global Strategy, Portfolio Mktg. & Business Dev and Global BioDevices & Platinum Performance -
How many employees does ZTS have?
-
Number of ZTS employees currently stands at 14500. ZTS operates from 10 Sylvan Way, Parsippany, NJ 07054, US.
-
Link for ZTS official website?
-
Official Website of ZTS is: https://www.zoetis.com
-
How do I contact ZTS?
-
ZTS could be contacted at phone #973 822 7000 and can also be accessed through its website. ZTS operates from 10 Sylvan Way, Parsippany, NJ 07054, US.
-
How many shares of ZTS are traded daily?
-
The average number of ZTS shares traded daily for last 3 months was 7.34M.
-
What is the market cap of ZTS currently?
-
The market value of ZTS currently stands at $32.1B with its latest stock price at $76.56